Trade GTBP stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
GT Biopharma, Inc. (GTBP) is trading at US$7.16, down 4.41% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$13.02M. Over the past 52 weeks, GTBP has traded between US$4.91 and US$34.25. On Syfe you can trade GTBP with $0 commission and add it to your watchlist.
| Previous close | US$7.49 |
|---|---|
| Market cap | US$13.02M |
| 52-week range | US$4.91 – US$34.25 |
| Volume | 37.46K |
| Exchange | US |
Add to Watchlist
Set Price Alert
GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.
Year: 2021
GT Biopharma, Inc. (GTBP) stock is trading at US$7.16, -4.41% from the previous close of US$7.49.
The market cap for GT Biopharma, Inc. (GTBP) stock is approximately US$13.02M.
The 52-week high for GT Biopharma, Inc. (GTBP) stock is US$34.25.
The 52-week low for GT Biopharma, Inc. (GTBP) stock is US$4.91.
GT Biopharma, Inc. (GTBP) does not currently pay a dividend.
Stay on top of GTBP
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
